99logosm.gif (9586 bytes)98partic.jpg (13765 bytes)
june14.gif (2042 bytes)june15.gif (1936 bytes)


m1.gif (678 bytes)
98particia.gif (1489 bytes)
confer.gif (1268 bytes)
agen.gif (1587 bytes)
succ.gif (1797 bytes)
99spon.gif (1928 bytes)
spon.gif (2541 bytes)
supp.gif (2114 bytes)
presex.gif (2059 bytes)
hotacc.gif (2147 bytes)
direct.gif (1466 bytes)
nomcri.gif (2131 bytes)
appfrm.gif (1612 bytes)
reques.gif (1757 bytes)
regis.gif (2105 bytes)
address.gif (6114 bytes)


longwood.jpg (5545 bytes)

cclubbut.jpg (5092 bytes)

3223 Phoenixville Pike
Malvern, PA 19355
Ph: (610) 644-8990
Fax: (610) 644-8717

Katherine D. Crothall, President & CEO
Kusal Das, Principal Engineer (Mechanical)
Ian Shipway, Principal (Electrical)
Mike Sullivan, Principal Engineer (Optical)

Product Line or Service — Company is developing an insulin infusion pump and an implantable optical glucose sensor for insulin-dependent diabetics. The sensor will be a long-term implantable device (5 years or longer), will make measurements on a quasi continuous basis (once every two minutes), and will make a direct measurement of blood glucose as opposed to an inferred measurement (of some other body fluid). Dates of market introduction of pump and glucose sensor are mid-1999 and 2001, respectively. Ultimately, the Company plans to couple its sensor and pump together to provide closed-loop control of blood sugar.

Technology/Proprietary Rights — Pending patents (3) on the glucose sensor. No patents filed on insulin infusion pump although the company anticipates doing so. Scientific feasibility (in-vitro measurements) of sensor has been established on 500 + patients.

Market Opportunities — The company believes the ultimate market size for the insulin infusion pump is $ 0.5 billion and for the sensor is $ 1.2 billion. Current market size for pump is about $ 130 million. The company’s products can reduce or possibly eliminate both the acute and long-term complications of diabetes. In United States, the complications of diabetes are responsible for approximately 15 % of the total healthcare costs of the country.

Marketing/Sales and Distribution — None as of yet; however, the Company anticipates selling the pump through distributors and independent representatives both domestically and internationally. The Company also plans on hiring a network of independent nurses (per diem basis) to provide patient education and training. The Company has not yet formulated a distribution plan for the sensor.

Competition — In pump market, Minimed ($80M revenues) and Disetronics ($50M revenues). There is no implantable or minimally-invasive/ non-invasive sensor on the market although there are many groups attempting to develop such a sensor. The Animas device overcomes the signal-to-noise and artifact limitations of transcutaneous optical sensors and the encapsulation tissue limitations of implantable chemical/electro-chemical sensors.

Manufacturing — The Company intends to do assembly and final test of both sensor and pump in house. Components will be manufactured by outside vendors in accordance with specifications.

dates99b.gif (7133 bytes)